Skip to main content
Equibles

SENORES · Senores Pharmaceuticals Limited

Use SENORES with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SENORES.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,174.60 INR -42.40 (-3.48%) At close · Nov 13
Rebalance outlook locked
Market Cap
54.09B INR
Shares
46.05M
Volume · Nov 13 409.5K Avg daily vol (3M) 277.8K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close1,174.60 INR Open1,208.00 INR Day1,165.00–1,227.00 INR 52W close710.25–1,550.90 INR Avg vol 30d331K Last earningsOct 29, 2026 DataDec 2024–Nov 2026

Latest documents

2026
Oct 29
Earnings call
Record Q2 FY27 revenue, FY27 guidance maintained

Senores Pharmaceuticals Limited reported record Q2 FY27 revenue of INR192 crores, up 25% Y-o-Y, with EBITDA at INR58 crores and PAT around INR36.6 crores. Management maintained FY27 guidance for 30% to 40% revenue growth and 50% to 60% PAT growth.

3 source passages
the consolidated revenue from operations for Q2 FY27 stood at INR192 crores, which as Swapnil said is the highest for us, reflecting a very healthy growth of 25% Y-o-Y. Consolidated EBITDA for Q2 2027 stood at INR58 crores, growing by 38% Y-o-Y and EBITDA margin stood at 30%, which improved by 290 bps year-on-year. Profit after tax for the quarter grew by 22% Y-o-Y and came to around INR36.6 crores. we remain on track to achieve our FY27 guidance of 30% to 40% revenue growth and corresponding 50% to 60% PAT growth. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
· 1.03B INR 171.82M INR '25 Q3 · 1.14B INR 179.70M INR '25 Q4 · 1.38B INR 197.30M INR '26 Q1 · 1.62B INR 323.80M INR '26 Q2 ▲69.4% 1.75B INR 316.60M INR '26 Q3 ▲53.4% 1.75B INR 0 INR '26 Q4 ▲30.6% 1.80B INR 307.15M INR '27 Q1 LATEST ▲18.9% 1.92B INR 394.90M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 710.25 INR Now 1,174.60 INR · 55% Range high 1,550.90 INR
vs 200-day avg +4% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:SENORES +1.2% -6.7% +5.7% +3.6% +42.9%

Exchange listing

Market
XNSE
Ticker
SENORES
ISIN
INE0RB801010
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.senorespharma.com/
Investor relations
https://senorespharma.com/investor-meet/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-10-29 Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-07-27 Transcript
    Earnings Call
  • Earnings call · Q4 2026 2026-05-14 Transcript
    Earnings Call